Protagonist Therapeutics Inc Stock News

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 2.53% and 16.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

NEWARK, Calif., Feb. 28, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. "This past quarter and the year leading up…

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 2.53% and 16.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

In last trading session, Protagonist Therapeutics Inc. (NASDAQ:PTGX) saw 0.54 million shares changing hands with its beta currently measuring 2.28. Company’s recent per share price level of $24.49 trading at $0.24 or 0.99% at ring of the bell on the day assigns it a market valuation of $1.20B. That closing price of PTGX’s stock is … Protagonist Therapeutics Inc. (NASDAQ:PTGX) Is Likely To Perform Well Over The Long Term. Lost Nearly -13.83% Last Month. Read More »

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 50.77% and 21.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

Protagonist Therapeutics (PTGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in t

Protagonist Therapeutics (PTGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in t

Protagonist Therapeutics is currently working to tackle some serious issues with an underserved form of blood cancer. A recent cancer scare sent shockwaves through the company's valuation, and it has

In this article we will check out the progression of hedge fund sentiment towards Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and determine whether it is a good investment right now.

Protagonist Therapeutics (NASDAQ:PTGX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Profitability This table compares Protagonist Therapeutics and Syndax Pharmaceuticals net margins, return on equity and []

Wall Street brokerages expect that Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will report $7.38 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Protagonist Therapeutics earnings. The lowest sales estimate is $7.00 million and the highest is $7.50 million. Protagonist Therapeutics reported sales of $5.65 million during the same []

Equities analysts expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to report ($0.79) earnings per share for the current quarter, according to Zacks. Four analysts have provided estimates for Protagonist Therapeutics earnings. The highest EPS estimate is ($0.70) and the lowest is ($0.97). Protagonist Therapeutics posted earnings of ($0.48) per share during the same quarter last year, which []

Jabodon PT Co. purchased a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the third quarter, HoldingsChannel.com reports. The institutional investor purchased 90,656 shares of the companys stock, valued at approximately $1,606,000. Protagonist Therapeutics makes up about 0.7% of Jabodon PT Co.s investment portfolio, making the stock its 25th biggest position. Several other []

Millennium Management LLC lifted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 41.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 15,440 shares of the company’s stock after purchasing an additional 4,548 shares during the period. Millennium Management LLC’s holdings in Protagonist Therapeutics were worth $693,000 as […]